Brain metastases in patients with low-grade endometrial carcinoma

Abstract Cerebrospinal fluid (CSF) baths extracellular environment of the central nervous system, and thus, it is ideal source of tumor diagnostic biomarkers like microRNAs (miRNAs), short non-coding RNAs involved in the pathogenesis of many cancers. As dysregulated levels of brain tumor specific miRNAs have been already observed in CSF, analysis of CSF miRNAs in brain tumor patients might help to develop new diagnostic platform. Next-Generation sequencing (NGS) was performed for analysis of small RNAs in 89 CSF samples taken from 32 glioblastomas (GBM), 14 low-grade gliomas (LGG), 11 meningiomas, 13 brain metastases and 19 non-tumor donors. Subsequently, according to NGS results levels of 10 miRNAs were measured in independent set of CSF samples (41 GBM, 44 meningiomas, 12 brain metastases and 20 non-tumor donors) using TaqMan Advanced miRNA Assays. NGS analysis revealed 22, 12 and 35 CSF miRNAs with significantly different levels in GBM, meningiomas, and brain metastases (adj.p < 0.0005, adj.p < 0.01, and adj.p < 0.005) respectively, in comparison with non-tumor CSF samples. Subsequent validation of selected CSF miRNAs has confirmed different levels of 7 miRNAs in GBM, 2 in meningiomas, and 2 in brain metastases compared to non-tumors. Panel of miR-30e-5p and miR-140-5p was able to distinguish brain metastases with 65% sensitivity and 100% specificity compared to non-tumor samples (AUC = 0.8167); panel of miR-21-3p and miR-196-5p classified metastatic patients with 78% sensitivity and 92 % specificity in comparison to GBM (AUC = 0.90854) and with 75% sensitivity and 83% specificity compared to meningiomas (AUC = 0.84848). We have observed that CSFs from patients with various primary brain tumors and metastases are characterized by specific miRNA signatures. This work was supported by the Ministry of Health, Czech Republic grant nr. NV18-03-00398 and the Ministry of Education, Youth and Sports, Czech Republic under the project CEITEC 2020 (LQ1601).

Download Full-text

Controversies in the Management of Endometrial Carcinoma

Obstetrics and Gynecology International ◽

10.1155/2010/862908 ◽

2010 ◽

Vol 2010 ◽

pp. 1-16 ◽

Cited By ~ 8

Author(s):

Ying Zhang ◽

Jian Wang

Keyword(s):

High Risk ◽

Endometrial Carcinoma ◽

Operative Procedure ◽

Female Genital Tract ◽

Risk Groups ◽

Low Grade ◽

Radiation Delivery ◽

Postoperative Irradiation ◽

Systemic Therapies ◽

Female Genital

Endometrial carcinoma is the most common type of female genital tract malignancy. Although endometrial carcinoma is a low grade curable malignancy, the condition of the disease can range from excellent prognosis with high curability to aggressive disease with poor outcome. During the last 10 years many researches have provided some new valuable data of optimal treatments for endometrial carcinoma. Progression in diagnostic imaging, radiation delivery systems, and systemic therapies potentially can improve outcomes while minimizing morbidity. Firstly, total hysterectomy and bilateral salphingo-oophorectomy is the primary operative procedure. Pelvic lymhadenectomy is performed in most centers on therapeutic and prognostic grounds and to individualize adjuvant treatment. Women with endometrial carcinoma can be readily segregated intraoperatively into “low-risk” and “high-risk” groups to better identify those women who will most likely benefit from thorough lymphadenectomy. Secondly, adjuvant therapies have been proposed for women with endometrial carcinoma postoperatively. Postoperative irradiation is used to reduce pelvic and vaginal recurrences in high risk cases. Chemotherapy is emerging as an important treatment modality in advanced endometrial carcinoma. Meanwhile the availability of new hormonal and biological agents presents new opportunities for therapy.

Download Full-text

Successful treatment with stereotactic radiosurgery for brain metastases of endometrial carcinoma: A case report and review of the literature

International Journal of Gynecological Cancer ◽

10.1046/j.1525-1438.2003.13017.x ◽

2003 ◽

Vol 13 (1) ◽

pp. 71-76 ◽

Cited By ~ 14

Author(s):

s. shiohara ◽

m. ohara ◽

k. itoh ◽

t. shiozawa ◽

i. konishi

Keyword(s):

Case Report ◽

Brain Metastases ◽

Endometrial Carcinoma ◽

Stereotactic Radiosurgery ◽

Successful Treatment ◽

Review Of The Literature

Download Full-text

DNA-content in endometrial carcinoma of tamoxifen-treated breast cancer patients

International Journal of Gynecological Cancer ◽

10.1046/j.1525-1438.1994.04020131.x ◽

1994 ◽

Vol 4 (2) ◽

pp. 131-134

Author(s):

B. Moberger ◽

T. Fornander ◽

A-C. HellstrÖM

Keyword(s):

Breast Cancer ◽

Endometrial Carcinoma ◽

Dna Content ◽

Clinical Importance ◽

Tamoxifen Therapy ◽

Adjuvant Tamoxifen ◽

Low Grade ◽

Breast Cancer Patients ◽

Beneficial Effects ◽

Histopathologic Evaluation

DNA measurements and histopathologic evaluation were performed in 17 patients treated with adjuvant tamoxifen for early breast cancer and who developed endometrial carcinoma during or after the tamoxifen therapy. The tumors were exclusively characterized by euploid DNA content except for two cases, one mixed mesodermal sarcoma, a highly malignant and rare tumor, and one adenocarcinoma. Although the use of adjuvant tamoxifen therapy most likely enhances the risk of developing endometrial carcinoma, the beneficial effects of adjuvant breast cancer treatment is of well-known clinical importance. The hazards of giving long-term tamoxifen seem to be low since the endometrial tumors were associated with low-grade malignancy and euploid DNA pattern.

Download Full-text